Next Article in Journal
Quantification of 6-Mercaptopurine and Its Metabolites in Patients with Acute Lympoblastic Leukemia Using Dried Blood Spots and UPLC-MS/MS
Previous Article in Journal
Ocular Delivery System for Propranolol Hydrochloride Based on Nanostructured Lipid Carrier
Article Menu

Export Article

Open AccessArticle
Sci. Pharm. 2018, 86(2), 17; https://doi.org/10.3390/scipharm86020017

Betulin-3,28-diphosphate as a Component of Combination Cytostatic Drugs for the Treatment of Ehrlich Ascites Carcinoma In Vitro and In Vivo Experiments

1
Department of Pharmaceutical Chemistry, Federal State Budgetary Educational Institution of Higher Education “Privolzhsky Research Medical University”, Ministry of Health of the Russian Federation, Minin sq., 10/1, 603005 Nizhny Novgorod, Russia
2
Department of Chemistry, N.P. Ogarev Mordovian State University, Bolshevistskaya St. 68, 430005 Saransk, Russia
*
Author to whom correspondence should be addressed.
Received: 28 February 2018 / Revised: 17 April 2018 / Accepted: 18 April 2018 / Published: 23 April 2018
Full-Text   |   PDF [1702 KB, uploaded 3 May 2018]   |  

Abstract

The activity of betulin-3,28-diphosphate (BDP) in combination with the cytostatics such as 5-fluorouracil (5-FU) and hydrazine sulfate (HS) was demonstrated by using the transplanted Ehrlich ascites carcinoma (EAC) in mice. The dose-dependent effect of combination drugs BDP + HS and BDP + 5-FU was revealed by in vitro experiments on rats. The synergetic effect of HS and BDP on oxidative stress and energy metabolism was established. The malonic dialdehyde (MDA) level both in plasma and erythrocytes decreased by 87 ± 2%, and the superoxide dismutase (SOD) activity increased by 105 ± 7% in comparison with the control. The combination of BDP + HS promoted the increase of lactate dehydrogenase (LDH) activity in the reverse reaction by 195 ± 21% compared to the control. The combination drug of 5-FU with BDP caused the synergetic decrease of the lipid peroxidation (LPO) intensity estimated by the MDA level decrease up to 14 ± 4% compared to pure compounds. Betulin-3,28-diphosphate in combination with cytostatics for EAC treatment improved the animal health status, as well as decreased the cytostatics dose that can be used in palliative therapy. View Full-Text
Keywords: Ehrlich carcinoma; betulin-3,28-diphosphate; 5-fluorouracil; hydrazine sulfate; antioxidant activity Ehrlich carcinoma; betulin-3,28-diphosphate; 5-fluorouracil; hydrazine sulfate; antioxidant activity
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Vorobyova, O.; Deryabina, O.; Malygina, D.; Plotnikova, N.; Solovyeva, A.; Belyaeva, K.; Melnikova, N. Betulin-3,28-diphosphate as a Component of Combination Cytostatic Drugs for the Treatment of Ehrlich Ascites Carcinoma In Vitro and In Vivo Experiments. Sci. Pharm. 2018, 86, 17.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top